105.65 USD
+0.1 (+0.09%)
105.705 USD
+0.05 (+0.05%)
We assign a fundamental rating of 7 out of 10 to INCY. INCY was compared to 533 industry peers in the Biotechnology industry. INCY gets an excellent profitability rating and is at the same time showing great financial health properties. INCY scores decently on growth, while it is valued quite cheap. This could make an interesting combination. With these ratings, INCY could be worth investigating further for value and quality investing!.
1. Profitability
1.1 Basic Checks
INCY had positive earnings in the past year.
INCY had a positive operating cash flow in the past year.
Of the past 5 years INCY 4 years were profitable.
INCY had a positive operating cash flow in 4 of the past 5 years.
1.2 Ratios
INCY has a Return On Assets of 18.78%. This is amongst the best in the industry. INCY outperforms 96.62% of its industry peers.
INCY's Return On Equity of 25.55% is amongst the best of the industry. INCY outperforms 96.81% of its industry peers.
Looking at the Return On Invested Capital, with a value of 19.88%, INCY belongs to the top of the industry, outperforming 97.56% of the companies in the same industry.
Measured over the past 3 years, the Average Return On Invested Capital for INCY is significantly below the industry average of 18.83%.
The 3 year average ROIC (7.24%) for INCY is below the current ROIC(19.88%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.78% | ||
| ROE | 25.55% | ||
| ROIC | 19.88% |
ROA(3y)5.08%
ROA(5y)5.23%
ROE(3y)6.75%
ROE(5y)6.82%
ROIC(3y)7.24%
ROIC(5y)N/A
1.3 Margins
INCY's Profit Margin of 24.69% is amongst the best of the industry. INCY outperforms 95.12% of its industry peers.
INCY's Profit Margin has declined in the last couple of years.
INCY has a better Operating Margin (26.10%) than 95.87% of its industry peers.
In the last couple of years the Operating Margin of INCY has declined.
INCY's Gross Margin of 93.47% is amongst the best of the industry. INCY outperforms 93.62% of its industry peers.
INCY's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 26.1% | ||
| PM (TTM) | 24.69% | ||
| GM | 93.47% |
OM growth 3Y-50.23%
OM growth 5Y-33.03%
PM growth 3Y-71.07%
PM growth 5Y-48.24%
GM growth 3Y-0.87%
GM growth 5Y-0.53%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), INCY is creating value.
Compared to 1 year ago, INCY has less shares outstanding
INCY has less shares outstanding than it did 5 years ago.
The debt/assets ratio for INCY is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 9.33 indicates that INCY is not in any danger for bankruptcy at the moment.
INCY's Altman-Z score of 9.33 is amongst the best of the industry. INCY outperforms 81.05% of its industry peers.
INCY has a debt to FCF ratio of 0.03. This is a very positive value and a sign of high solvency as it would only need 0.03 years to pay back of all of its debts.
The Debt to FCF ratio of INCY (0.03) is better than 96.25% of its industry peers.
A Debt/Equity ratio of 0.01 indicates that INCY is not too dependend on debt financing.
INCY has a Debt to Equity ratio of 0.01. This is comparable to the rest of the industry: INCY outperforms 45.78% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.03 | ||
| Altman-Z | 9.33 |
ROIC/WACC2.3
WACC8.63%
2.3 Liquidity
INCY has a Current Ratio of 3.20. This indicates that INCY is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of INCY (3.20) is worse than 61.54% of its industry peers.
A Quick Ratio of 3.13 indicates that INCY has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 3.13, INCY is in line with its industry, outperforming 40.71% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.2 | ||
| Quick Ratio | 3.13 |
3. Growth
3.1 Past
INCY shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 575.79%, which is quite impressive.
Measured over the past years, INCY shows a very negative growth in Earnings Per Share. The EPS has been decreasing by -14.21% on average per year.
Looking at the last year, INCY shows a quite strong growth in Revenue. The Revenue has grown by 18.09% in the last year.
INCY shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 14.46% yearly.
EPS 1Y (TTM)575.79%
EPS 3Y-21.7%
EPS 5Y-14.21%
EPS Q2Q%111.21%
Revenue 1Y (TTM)18.09%
Revenue growth 3Y12.41%
Revenue growth 5Y14.46%
Sales Q2Q%20.05%
3.2 Future
The Earnings Per Share is expected to grow by 29.50% on average over the next years. This is a very strong growth
INCY is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 0.60% yearly.
EPS Next Y427.7%
EPS Next 2Y144.97%
EPS Next 3Y89.5%
EPS Next 5Y29.5%
Revenue Next Year18%
Revenue Next 2Y14.17%
Revenue Next 3Y12.54%
Revenue Next 5Y0.6%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 16.46, which indicates a correct valuation of INCY.
Based on the Price/Earnings ratio, INCY is valued cheaper than 95.12% of the companies in the same industry.
INCY is valuated rather cheaply when we compare the Price/Earnings ratio to 26.15, which is the current average of the S&P500 Index.
Based on the Price/Forward Earnings ratio of 13.34, the valuation of INCY can be described as correct.
INCY's Price/Forward Earnings ratio is rather cheap when compared to the industry. INCY is cheaper than 97.00% of the companies in the same industry.
INCY is valuated cheaply when we compare the Price/Forward Earnings ratio to 36.12, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.46 | ||
| Fwd PE | 13.34 |
4.2 Price Multiples
INCY's Enterprise Value to EBITDA ratio is rather cheap when compared to the industry. INCY is cheaper than 95.87% of the companies in the same industry.
95.31% of the companies in the same industry are more expensive than INCY, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 17.24 | ||
| EV/EBITDA | 12.8 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of INCY may justify a higher PE ratio.
A more expensive valuation may be justified as INCY's earnings are expected to grow with 89.50% in the coming years.
PEG (NY)0.04
PEG (5Y)N/A
EPS Next 2Y144.97%
EPS Next 3Y89.5%
5. Dividend
5.1 Amount
INCY does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
105.65
+0.1 (+0.09%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners103.23%
Inst Owner Change1.17%
Ins Owners1.85%
Ins Owner Change-5.63%
Market Cap20.63B
Revenue(TTM)4.81B
Net Income(TTM)1.19B
Analysts73.33
Price Target94.53 (-10.53%)
Short Float %4.98%
Short Ratio4.37
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)19.23%
Min EPS beat(2)4.72%
Max EPS beat(2)33.74%
EPS beat(4)3
Avg EPS beat(4)10.09%
Min EPS beat(4)-10.01%
Max EPS beat(4)33.74%
EPS beat(8)3
Avg EPS beat(8)-1.54%
EPS beat(12)6
Avg EPS beat(12)-3.05%
EPS beat(16)7
Avg EPS beat(16)-8.28%
Revenue beat(2)2
Avg Revenue beat(2)5.08%
Min Revenue beat(2)3.45%
Max Revenue beat(2)6.72%
Revenue beat(4)4
Avg Revenue beat(4)3.8%
Min Revenue beat(4)1.09%
Max Revenue beat(4)6.72%
Revenue beat(8)5
Avg Revenue beat(8)1.4%
Revenue beat(12)7
Avg Revenue beat(12)0.24%
Revenue beat(16)9
Avg Revenue beat(16)0.48%
PT rev (1m)10.04%
PT rev (3m)12.54%
EPS NQ rev (1m)6.88%
EPS NQ rev (3m)6.87%
EPS NY rev (1m)10.24%
EPS NY rev (3m)10.09%
Revenue NQ rev (1m)2.46%
Revenue NQ rev (3m)2.84%
Revenue NY rev (1m)2.47%
Revenue NY rev (3m)2.64%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 16.46 | ||
| Fwd PE | 13.34 | ||
| P/S | 4.29 | ||
| P/FCF | 17.24 | ||
| P/OCF | 16.49 | ||
| P/B | 4.44 | ||
| P/tB | 4.71 | ||
| EV/EBITDA | 12.8 |
EPS(TTM)6.42
EY6.08%
EPS(NY)7.92
Fwd EY7.5%
FCF(TTM)6.13
FCFY5.8%
OCF(TTM)6.41
OCFY6.07%
SpS24.65
BVpS23.82
TBVpS22.41
PEG (NY)0.04
PEG (5Y)N/A
Graham Number58.66
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 18.78% | ||
| ROE | 25.55% | ||
| ROCE | 25.17% | ||
| ROIC | 19.88% | ||
| ROICexc | 48.14% | ||
| ROICexgc | 55.55% | ||
| OM | 26.1% | ||
| PM (TTM) | 24.69% | ||
| GM | 93.47% | ||
| FCFM | 24.87% |
ROA(3y)5.08%
ROA(5y)5.23%
ROE(3y)6.75%
ROE(5y)6.82%
ROIC(3y)7.24%
ROIC(5y)N/A
ROICexc(3y)25.32%
ROICexc(5y)N/A
ROICexgc(3y)31.6%
ROICexgc(5y)N/A
ROCE(3y)9.17%
ROCE(5y)N/A
ROICexgc growth 3Y-34.92%
ROICexgc growth 5Y-33.44%
ROICexc growth 3Y-36.33%
ROICexc growth 5Y-29.08%
OM growth 3Y-50.23%
OM growth 5Y-33.03%
PM growth 3Y-71.07%
PM growth 5Y-48.24%
GM growth 3Y-0.87%
GM growth 5Y-0.53%
F-Score7
Asset Turnover0.76
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.01 | ||
| Debt/FCF | 0.03 | ||
| Debt/EBITDA | 0.02 | ||
| Cap/Depr | 59.08% | ||
| Cap/Sales | 1.13% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 92.81% | ||
| Profit Quality | 100.71% | ||
| Current Ratio | 3.2 | ||
| Quick Ratio | 3.13 | ||
| Altman-Z | 9.33 |
F-Score7
WACC8.63%
ROIC/WACC2.3
Cap/Depr(3y)83.51%
Cap/Depr(5y)185.09%
Cap/Sales(3y)1.73%
Cap/Sales(5y)3.66%
Profit Quality(3y)367.72%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)575.79%
EPS 3Y-21.7%
EPS 5Y-14.21%
EPS Q2Q%111.21%
EPS Next Y427.7%
EPS Next 2Y144.97%
EPS Next 3Y89.5%
EPS Next 5Y29.5%
Revenue 1Y (TTM)18.09%
Revenue growth 3Y12.41%
Revenue growth 5Y14.46%
Sales Q2Q%20.05%
Revenue Next Year18%
Revenue Next 2Y14.17%
Revenue Next 3Y12.54%
Revenue Next 5Y0.6%
EBIT growth 1Y6374.01%
EBIT growth 3Y-44.05%
EBIT growth 5Y-23.34%
EBIT Next Year352.21%
EBIT Next 3Y84.5%
EBIT Next 5Y26.81%
FCF growth 1Y106.03%
FCF growth 3Y-24.05%
FCF growth 5Y-17.01%
OCF growth 1Y97.88%
OCF growth 3Y-23.52%
OCF growth 5Y-13.95%
INCYTE CORP / INCY FAQ
What is the fundamental rating for INCY stock?
ChartMill assigns a fundamental rating of 7 / 10 to INCY.
What is the valuation status for INCY stock?
ChartMill assigns a valuation rating of 8 / 10 to INCYTE CORP (INCY). This can be considered as Undervalued.
How profitable is INCYTE CORP (INCY) stock?
INCYTE CORP (INCY) has a profitability rating of 7 / 10.
What is the valuation of INCYTE CORP based on its PE and PB ratios?
The Price/Earnings (PE) ratio for INCYTE CORP (INCY) is 16.46 and the Price/Book (PB) ratio is 4.44.
What is the earnings growth outlook for INCYTE CORP?
The Earnings per Share (EPS) of INCYTE CORP (INCY) is expected to grow by 427.7% in the next year.